204 related articles for article (PubMed ID: 31265768)
1. The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population.
Bassir Nia A; Mann CL; Spriggs S; DeFrancisco DR; Carbonaro S; Parvez L; Galynker II; Perkel CA; Hurd YL
J Clin Psychiatry; 2019 Jul; 80(4):. PubMed ID: 31265768
[TBL] [Abstract][Full Text] [Related]
2. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis.
Bassir Nia A; Medrano B; Perkel C; Galynker I; Hurd YL
J Psychopharmacol; 2016 Dec; 30(12):1321-1330. PubMed ID: 27462088
[TBL] [Abstract][Full Text] [Related]
3. Psychosis and synthetic cannabinoids.
Deng H; Verrico CD; Kosten TR; Nielsen DA
Psychiatry Res; 2018 Oct; 268():400-412. PubMed ID: 30125871
[TBL] [Abstract][Full Text] [Related]
4. Cannabis, cannabinoids, and health.
Lafaye G; Karila L; Blecha L; Benyamina A
Dialogues Clin Neurosci; 2017 Sep; 19(3):309-316. PubMed ID: 29302228
[TBL] [Abstract][Full Text] [Related]
5. [Cannabis and cannabinoids as drugs].
Khiabani HZ; Mørland J
Tidsskr Nor Laegeforen; 2007 Mar; 127(5):579-82. PubMed ID: 17332810
[TBL] [Abstract][Full Text] [Related]
6. Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs.
Chase PB; Hawkins J; Mosier J; Jimenez E; Boesen K; Logan BK; Walter FG
Clin Toxicol (Phila); 2016; 54(1):14-9. PubMed ID: 26653952
[TBL] [Abstract][Full Text] [Related]
7. Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset.
Martinotti G; Santacroce R; Papanti D; Elgharably Y; Prilutskaya M; Corazza O
CNS Neurol Disord Drug Targets; 2017; 16(5):567-575. PubMed ID: 28412921
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of Synthetic Cannabinoid and Cannabis Users Admitted to a Psychiatric Hospital: A Comparative Study.
Shalit N; Barzilay R; Shoval G; Shlosberg D; Mor N; Zweigenhaft N; Weizman A; Krivoy A
J Clin Psychiatry; 2016 Aug; 77(8):e989-95. PubMed ID: 27379411
[TBL] [Abstract][Full Text] [Related]
9. First episode psychosis with and without the use of cannabis and synthetic cannabinoids: Psychopathology, global functioning and suicidal ideation and antipsychotic effectiveness.
Ricci V; Ceci F; Di Carlo F; Di Muzio I; Ciavoni L; Santangelo M; Di Salvo G; Pettorruso M; Martinotti G; Maina G
Psychiatry Res; 2023 Feb; 320():115053. PubMed ID: 36682093
[TBL] [Abstract][Full Text] [Related]
10. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
van Amsterdam J; Brunt T; van den Brink W
J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
[TBL] [Abstract][Full Text] [Related]
11. Synthetic cannabinoid use in psychiatric patients and relationship to hospitalisation: A retrospective electronic case register study.
Hobbs M; Patel R; Morrison PD; Kalk N; Stone JM
J Psychopharmacol; 2020 Jun; 34(6):648-653. PubMed ID: 32108548
[TBL] [Abstract][Full Text] [Related]
12. Retrospective Chart Review of Synthetic Cannabinoid Intoxication with Toxicologic Analysis.
Sud P; Gordon M; Tortora L; Stripp M; Borg D; Berman A
West J Emerg Med; 2018 May; 19(3):567-572. PubMed ID: 29760857
[TBL] [Abstract][Full Text] [Related]
13. A survey of synthetic cannabinoid consumption by current cannabis users.
Gunderson EW; Haughey HM; Ait-Daoud N; Joshi AS; Hart CL
Subst Abus; 2014; 35(2):184-9. PubMed ID: 24821356
[TBL] [Abstract][Full Text] [Related]
14. New-Onset Prolonged Psychosis Following Synthetic Cannabinoid Use in an Older Patient: A Case Report.
Alhassan A; Prahad SR; Burk BG; Fargason RE; Birur B
Psychopharmacol Bull; 2024 Mar; 54(1):33-39. PubMed ID: 38449474
[TBL] [Abstract][Full Text] [Related]
15. Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use.
Koch CD; Xu L; Curtis SA; Roberts JD; Bunch DR; El-Khoury JM
Clin Chim Acta; 2020 Nov; 510():515-521. PubMed ID: 32795544
[TBL] [Abstract][Full Text] [Related]
16. Critical Illness Secondary to Synthetic Cannabinoid Ingestion.
Kourouni I; Mourad B; Khouli H; Shapiro JM; Mathew JP
JAMA Netw Open; 2020 Jul; 3(7):e208516. PubMed ID: 32687586
[TBL] [Abstract][Full Text] [Related]
17. Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study.
Welter S; Lücke C; Lam AP; Custal C; Moeller S; Sörös P; Thiel CM; Philipsen A; Müller HHO
Eur Addict Res; 2017; 23(4):182-193. PubMed ID: 28848170
[TBL] [Abstract][Full Text] [Related]
18. Modulation of acute effects of delta-9-tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposure.
Colizzi M; McGuire P; Giampietro V; Williams S; Brammer M; Bhattacharyya S
Eur Neuropsychopharmacol; 2018 Jul; 28(7):850-862. PubMed ID: 29935939
[TBL] [Abstract][Full Text] [Related]
19. Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness.
Koethe D; Gerth CW; Neatby MA; Haensel A; Thies M; Schneider U; Emrich HM; Klosterkötter J; Schultze-Lutter F; Leweke FM
Schizophr Res; 2006 Dec; 88(1-3):142-50. PubMed ID: 17005373
[TBL] [Abstract][Full Text] [Related]
20. "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans.
Gunderson EW; Haughey HM; Ait-Daoud N; Joshi AS; Hart CL
Am J Addict; 2012; 21(4):320-6. PubMed ID: 22691010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
